Chronic chromosome 22 with the Ableson murine leukemia(ABL)

Chronic myeloid
leukaemia (CML) is a hematopoietic stem cell disorder characterized by the reciprocal
translocation between the long arms of chromosomes 9 and 22 1. Fusion of the
breakpoint cluster region (BCR) on chromosome 22 with the Ableson murine
leukemia(ABL) tyrosine of chromosome 9 results in a fusion gene called BCR-ABL.
This gene is a tyrosine kinase signaling protein that is always on, causing the
cell to divide uncontrollably
5. The K562 cell line was derived from a 53-yr-old female suffering
from Chronic myeloid leukaemia at the terminal stage of blast crisis 2. Apoptosis is a
process that occurs changes in cell include blebbing, cell rounding and
shrinkage, nuclear fragmentation, chromatin condensation, shedding of small
cellular fragments 3-4.

(R1R2C2=N3-N2(H)-C1(=S)N1R3R4)6 have been reported
that they have many of  bioactivities
such as antibacterial, antifungal, antittumoral, antiviral. Previous studies have
been shown that the properties of this family are related to metal ion
coordination and their metal complexes have more active than the free ligand.7 Brockman et al were
reported the effect of  antitumoral of pyridine-2-carboxaldehyde
thiosemicarbazone on L1210 leukemia8 but was found this compound can be toxic7. The si de effects of
these compound can be decreased by comlex with metal7. Hosseini-Yazdi et al synthesized  and characterizantion of methylthiosemicarbazone
complex with Zn (II). They showed that this compound has cytotoxic effect on
the KG1-a and K562 cell lines9.

In this study,
we investigated the growth inhibitory and cytotoxicity effects of methylthiosemicarbazone
complex with Zn2+ on human chronic myelogenous leukemia K562. Our
results showed that
methylthiosemicarbazone complex with Zn2+ inhibits the
growth of K562 cells via the induction of apoptosis. Our data indicate that methylthiosemicarbazone
complex with Zn2+ has potential role as a therapeutic factor to
induction of apoptosis and can be considered for its further development as an
antileukemia drug.



I'm Mary!

Would you like to get a custom essay? How about receiving a customized one?

Check it out